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Original Paper
Procedural and declarative memory task
performance, and the memory consolidation
function of sleep, in recent and abstinent
ecstasy/MDMA users
Mark Blagrove1, Jennifer Seddon1, Sophie George2,
Andrew C Parrott1, Robert Stickgold3, Matthew P Walker4,
Katy A Jones1 and Michael J Morgan2,5
Abstract
Ecstasy/MDMA use has been associated with various memory deficits. This study assessed declarative and procedural memory in ecstasy/MDMA users.
Participants were tested in two sessions, 24 h apart, so that the memory consolidation function of sleep on both types of memory could also be
assessed. Groups were: drug-naive controls (n¼ 24); recent ecstasy/MDMA users, who had taken ecstasy/MDMA 2–3 days before the first testing session
(n¼ 25), and abstinent users, who had not taken ecstasy/MDMA for at least 8 days before testing (n¼ 17). Procedural memory did not differ between
groups, but greater lifetime consumption of ecstasy was associated with poorer procedural memory. Recent ecstasy/MDMA users who had taken other
drugs (mainly cannabis) 48–24 h before testing exhibited poorer declarative memory than controls, but recent users who had not taken other drugs in
this 48–24-h period did not differ from controls. Greater lifetime consumption of ecstasy, and of cocaine, were associated with greater deficits in
declarative memory. These results suggest that procedural, as well as declarative, memory deficits are associated with the extent of past ecstasy use.
However, ecstasy/MDMA did not affect the memory consolidation function of sleep for either the declarative or the procedural memory task.
Keywords
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Introduction
Ecstasy is the street name for [þ/]-3,4-methylenedioxy-
methamphetamine (MDMA). There have been many reports
associating the use of ecstasy/MDMA with various memory
deﬁcits. This study aimed to examine the declarative and pro-
cedural memory performance of frequent ecstasy/MDMA
users, 2–3 days after recreational use of ecstasy/MDMA,
and during abstinence from ecstasy/MDMA, while control-
ling for various trait and state factors, including sleep length
prior to testing. It also aimed to assess the change in memory
across a 24-h period, so as to investigate the potential inﬂu-
ence of ecstasy/MDMA on sleep-dependent memory
consolidation.
Relative to drug-naive controls and polydrug controls, the
most consistent neurocognitive deﬁcit observed in recrea-
tional ecstasy/MDMA users has been poorer memory and
learning (Morgan, 1999; Parrott and Lasky, 1998; Rogers
et al., 2009; Zakzanis et al., 2007), although there are also
negative ﬁndings (e.g. Back-Madruga et al., 2003). These
memory deﬁcits can persist after prolonged abstinence from
ecstasy/MDMA (Morgan et al., 2002; Thomasius et al.,
2005). The sub-acute eﬀects of ecstasy/MDMA can also dis-
rupt mood and cognition, with signiﬁcant deﬁcits 2–4 days
after consumption, which are often followed by recovery from
the sub-acute eﬀect within approximately 7 days (Curran and
Travill, 1997; Curran et al., 2004; Huxster et al., 2006; Jones
et al., 2008; Parrott and Lasky, 1998, Verheyden et al., 2003).
In order to separate out these sub-acute deﬁcits from the
longer-term chronic psychobiological deﬁcits, we assessed
two groups of frequent ecstasy/MDMA users: those who
had taken ecstasy/MDMA in the previous 2–3 days, and
those who had not taken any ecstasy/MDMA in the 8 or
more days prior to testing. The ﬁrst aim was to compare
the performance of these two groups with controls on a
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declarative and a procedural memory task. The previous lit-
erature supports a prediction of deﬁcits in ecstasy/MDMA
users for the declarative task. The procedural task was
included so as to augment the limited literature on the rela-
tionship between ecstasy/MDMA use and psychomotor per-
formance, which does not support deﬁcits on such tasks
(Zakzanis et al., 2007), and because the speciﬁc task used,
the Finger Tapping Task, is the standard task for the assess-
ment of sleep-dependent memory consolidation.
The second aim was to assess whether ecstasy/MDMA
aﬀects the process of sleep-dependent memory consolidation.
A period of sleep on the night after a procedural learning task
can improve subsequent performance, despite no intervening
task practice (Stickgold, 2005; Walker, 2005). This eﬀect is
not due to reduced sleepiness (Walker et al., 2002). The sleep
eﬀect is also seen for declarative memory tasks (Axmacher
et al., 2008; Ellenbogen et al., 2009), but here usually refers
to a smaller deﬁcit in delayed recall performance after sleep
than after a similar period spent awake (Born and Gais,
2003).
It was hypothesized that the sleep-dependent consolidation
eﬀect for declarative and/or procedural memory might be
reduced or absent in ecstasy/MDMA users, because of the
drug’s disruptive eﬀects upon sleep (Carhart-Harris et al.,
2009; Huxster et al., 2006; Jones et al., 2008; Kirilly et al.,
2008; Pirona andMorgan, 2010). The hypothesized decrement
in procedural memory consolidation is also supported by the
ﬁnding of an enhancement of memory consolidation during
sleep, for the Finger Tapping Task, when acute selective sero-
tonin reuptake inhibitor (SSRI) administration occurred in
the period between learning and sleep (Rasch et al., 2009).
SSRI administration generally augments serotonin activity
(Beyer and Cremers, 2008), whereas serotonin deﬁciencies
are claimed to follow ecstasy/MDMA usage (Thomasius
et al., 2003; Walker et al., 2007), and may hence disrupt
sleep-dependent procedural memory consolidation.
The third aim was to take account of three areas of con-
found present in naturalistic studies of recreational ecstasy/
MDMA use. The ﬁrst of these is the co-use of other drugs,
which may themselves cause memory deﬁcits (Croft et al.,
2001; Gouzoulis-Mayfrank and Daumann, 2006; Lamers
et al., 2006; Parrott, 2006). The use of illegal drugs in the
24 h before testing was therefore an exclusion criterion for
the study. However, as there is evidence for ketamine
(Morgan et al., 2004), cocaine (Schierenbeck et al., 2008)
and cannabis (Pope et al., 2001) having cognitive eﬀects
that last longer than 24 h, after the initial analysis, using all
participants, the data were reanalysed having temporarily
excluded participants who reported any illegal drug use in
the 48–24-h period before testing. The second area of con-
founds is pre-morbid intelligence and personality diﬀerences
between ecstasy/MDMA users and non-users. The following
traits which may act as confounds of memory performance,
either directly or in interaction with drug use were proposed:
Locus of Control (Blagrove and Akehurst, 2001),
Conscientiousness (Saucier, 1994), and Morningness–
Eveningness, a measure of preference that the individual
has to do eﬀortful or intense work in the morning compared
with the evening. Self-reported usual time of maximum alert-
ness was also recorded. A third type of confound was pre-test
and during-test factors, such as length of sleep and alcohol/
caﬀeine/nicotine use prior to testing, and sleepiness during
testing.
To summarize, it was hypothesized that:
1. Declarative memory performance would be worse in
recent and abstinent ecstasy/MDMA users compared
with non-drug-using controls; and, with respect to the
memory consolidation function of sleep,
2. Recent and abstinent ecstasy/MDMA users would exhi-
bit a greater decrement in declarative memory perfor-
mance, following sleep, than non-drug-using controls;
3. Recent and abstinent ecstasy/MDMA users would show
a reduced improvement in procedural memory perfor-
mance, following sleep, compared with non-drug-using
controls.
No hypothesis was proposed about procedural memory
performance being poorer in recent and abstinent ecstasy/
MDMA users compared with non-drug-using controls, as
the current limited literature on this does not support such
a prediction. Also, the literature is unclear about the sub-
acute eﬀects of ecstasy/MDMA on memory, with some evi-
dence that recent use is associated with memory deﬁcits
(Parrott and Lasky, 1998) while other evidence suggests that
ecstasy/MDMA has no sub-acute eﬀects on memory after
controlling for baseline performance and other recent drug
use (Pirona and Morgan, 2010). The study thus included
both recent and abstinent ecstasy/MDMA groups, but no
prediction was made about whether memory deﬁcits in the
recent ecstasy/MDMA group would exceed those of the absti-
nent group.
Method
Participants and drug conditions
Recruitment was by advertisements for individuals who fre-
quently attend nightclubs: there was no mention of drugs in
the advertisements. This ensured that participants had a sim-
ilar nightclubbing social life, so that factors such as sporadic
late nights and intense dancing were controlled for, but also
that self-selection on the basis of drug use did not occur. Such
controlling for lifestyle did, however, result in diﬃculty in
ﬁnding non-drug taking controls who had never taken can-
nabis. It was thus decided to include in the control group
participants who had occasionally taken cannabis, but who
had not taken it within the last year. The exclusion criteria for
all participants were: a history of epilepsy, schizophrenia,
bipolar disorder, any intravenous drug use, or any serious
current medical condition that requires or has required
medication.
A total of 117 participants, all frequent night-clubbers,
were recruited following telephone screening using partici-
pants’ self-report for the exclusion criteria listed above. Of
the 117 participants recruited, 38 were excluded due to not
meeting the criteria for membership of the three experimental
groups. A further eight were excluded due to reporting taking
illegal drugs within the 24 h before either testing session. One
participant (control) was excluded because of alcohol use an
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hour prior to testing, and three recent ecstasy/MDMA users
and one abstinent ecstasy/MDMA user were excluded due to
their reported level of alcohol use in the evening/night prior to
testing (reported units for these four participants¼ 40, 30, 21,
and 30 respectively). The ﬁnal sample thus totalled 66 partic-
ipants, divided into three groups:
1. Control group (n¼ 24; mean age¼ 21.88 years
(SD¼ 3.51, range 18–29 years); 11 males, 13 females).
This comprised participants who reported having never
taken ecstasy or MDMA nor any other illegal drugs,
except for minor cannabis use (deﬁned as lifetime con-
sumption 10 joints) that was not within the last year.
Nine in this group (37.5%) reported having used canna-
bis at least once.
2. Recent ecstasy/MDMA group (n¼ 25; mean age¼ 21.44
years (SD¼ 2.40, range 18–28 years); 10 males, 15
females). This comprised regular ecstasy/MDMA users
(deﬁned as taking ecstasy and/or MDMA at least twice
per month) who reported taking ecstasy/MDMA 2–3
days before the ﬁrst performance testing session. The
group mean self-estimate of ecstasy/MDMA tablets con-
sumed during the 2–3 days prior to testing ¼ 2.88
(SD¼ 5.25, n¼ 25) and group mean self-estimate of
MDMA consumed¼ 0.35 g (SD¼ 0.42, n¼ 25). Ten par-
ticipants reported taking only ecstasy tablets, nine
reported taking only MDMA powder, and six reported
taking both ecstasy tablets and MDMA powder. The
means for participants who reported using each form of
MDMA are: ecstasy tablets, mean¼ 4.50 (SD¼ 6.03,
n¼ 16), and MDMA powder, mean¼ 0.58 g (SD¼ 0.40,
n¼ 15).
3. Abstinent ecstasy/MDMA group (n¼ 17; mean
age¼ 22.29 years (SD¼ 3.26, range 18–29 years); 8
males, 9 females). This comprised regular (deﬁned as
above) ecstasy/MDMA users who reported not taking
ecstasy or MDMA for 8 days or more before the ﬁrst
performance testing session. Period of abstinence from
ecstasy/MDMA for this group ranged from 8–28 days
before the ﬁrst performance testing session.
Measures
1. Sleep questionnaire. This included questions on usual
time of going to sleep and waking up on work and on
rest days, and usual sleep quality (‘during the last month,
how would you rate your sleep quality overall: 1¼ very
good, 2¼ fairly good, 3¼ fairly bad, 4¼ very bad’).
2. Drug history questionnaire, combining the General Drug
Use History Questionnaire (GDUQ); (Huxster et al., 2006)
and the UEL Drug History Questionnaire (Parrott et al.,
2000). This questionnaire recorded current frequency and
usual dose of drugs consumed, and lifetime drug usage.
3. The previous 24 h drug use questionnaire. This assessed
self-reported drug use, and caﬀeine, alcohol and nicotine
use, in the 24 h prior to each performance testing session.
4. The 50 word, National Adult Reading Test (NART)
(Nelson, 1982). This provides an estimate of pre-morbid
full IQ.
5. The short mini-markers version of the Big-5 personality
inventory (Saucier, 1994), to assess Conscientiousness.
6. The Composite Morningness Scale (Smith et al., 1989).
This assesses preferred times of day for alert eﬀortful
activity. Higher scores represent Morningness.
7. Locus of Control questionnaire (Levenson, 1981). This
assesses level of belief in whether events or aspects of
one’s life are under one’s internal control.
8. Daily diary for recording drug use, sleep times and mood.
The diary included, for each day, items recording any
drugs taken during the day, and the quantities of these,
time of going to bed, time taken to fall asleep, time of
waking, and also items on self-assessed mood. For mood,
participants completed two 10 cm visual analogue scales:
(i) anchored as Very tense (score¼ 0) to Very relaxed
(score¼ 100) and (ii) anchored as Very happy (score¼ 0)
to Very sad (score¼ 100).
9. The Story Memory Subtest (version B) from the
Rivermead Behavioral Memory Test (RBMT) (Wilson
et al., 1985). This involves the participant listening to a
65-word newspaper-type story concerning the ﬁghting of
a ﬁre. Free recall was assessed immediately, then after a
delay of 20min, and then 24 h later, and scored each time
for recall of the 21 idea components.
10. The Finger Tapping Task (FTT) (Walker et al., 2002).
The FTT involves typing the numbers 4-1-3-2-4 on a
keypad for 12 trials of 30 s each, with a break of 30 s
between each trial. Speed is calculated as the number of
correct sequences typed in 30 s. The crucial comparison is
between the mean speed of the last three trials on the ﬁrst
testing session and the mean speed of the ﬁrst three trials
on the second testing session, which was 24 h later. Error
rate was also assessed.
11. The Stanford Sleepiness Scale (SSS) (Hoddes et al., 1973).
This is a state measure of sleepiness, with items ranging
from 1¼ ‘Feeling active, vital, alert, wide awake’, to
7¼ ‘Almost in reverie, cannot stay awake, sleep onset
appears imminent’.
Procedure
Institutional ethics approval was obtained and strict conﬁden-
tiality of all data was guaranteed. Participants attended an
initial questionnaire session at which written and informed
consent was obtained from all participants. Participants
then completed demographic details, the Sleep questionnaire,
the Morningness Questionnaire, the NART, and the Drug
history questionnaire. Hair assays were not used to conﬁrm
self-reports of ecstasy/MDMA use as ethical issues would
have resulted from the holding of such objective evidence of
illegal activity, and because it may have reduced the number
of people willing to take part in the study. Substance depen-
dence was not assessed. Participants then took home the daily
diary for recording sleep times, mood and drug use. The diary
was completed for 5–10 days, depending upon the period
between the initial questionnaire session and the performance
testing sessions.
The ﬁrst performance testing session occurred the follow-
ing week, usually in an afternoon but sometimes in the
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early evening. The session comprised: the previous 24 h drug
use questionnaire; the SSS; RBMT story presentation and
immediate recall; FTT; Locus of Control questionnaire;
20min delayed RBMT recall, and SSS.
The second testing session occurred exactly 24 h later. Due
to the variability of sleep times for the illicit drug taking partic-
ipants it was not possible to utilize the usual sleep-dependent
memory consolidation design of 10:00 h and 22:00 h (i.e., wake
condition) versus 22:00 h and 10:00 h (i.e., sleep condition) test-
ing times. Tests: Previous 24 h drug use questionnaire; SSS; 24 h
delayed RBMT recall; FTT; Big-5 mini-markers, and SSS. At
this session the completed daily sleep and drug use diary was
returned to the experimenters.
Participants were asked not to take illegal drugs in the 24 h
prior to each performance testing session, and not to take
alcohol for 12 h prior to testing. Anyone who did report
doing so was tested and paid for their participation, but
was not included in any of the analyses.
Statistics
The data were ﬁrst analysed with SPSS version 13. The
groups were compared for sleep, personality and drug use
variables using one-way analyses of variance (ANOVAs) or
Kruskal-Wallis/Mann-Whitney tests, depending upon nor-
mality of the data. Repeated measures ANOVAs for the
RBMT and FTT scores were performed, with group as a
between-subjects factor. Planned comparisons in these
ANOVAs were between recent ecstasy/MDMA users and
controls, and between abstinent ecstasy/MDMA users and
controls, and the threshold p value for each of the two
between groups comparisons is thus set at 0.025. Simple
main eﬀects were also computed at each of the test times.
As the previous literature supports a prediction of deﬁcits in
declarative memory, one-tailed tests are used for the analysis
of planned comparisons and simple main eﬀects on the
declarative task. Regressions of RBMT and of FTT perfor-
mance on the continuous variable recency of ecstasy/MDMA
use were then conducted. Recency of ecstasy/MDMA use was
not normally distributed and so non-parametric rank regres-
sion was performed (Hettmansperger and McKean, 1998),
using the RREG procedure on Minitab version 15
(Hollander and Wolfe, 1999). These regression analyses are
reported immediately after the corresponding between-groups
repeated measures ANOVAs. As an association was found
between recency of ecstasy/MDMA use and RBMT score,
the potential confounding variables (e.g. NART IQ, gender,
mood, personality) were then investigated by being sequen-
tially entered into the regression equation. The repeated mea-
sures ANOVAs were then re-run excluding participants who
reported having taken illegal drugs in the period 48–24 h
before testing, and the interaction found between recent
ecstasy/MDMA use and recent other drug use on the
RBMT was investigated further.
The repeated measures analyses were then further re-run
using only participants who had obtained at least 7 h sleep
prior to each of the two performance testing days. The
group test day interaction was computed for the two tasks
in order to establish if the groups diﬀered in the change of
memory over the 24 h, i.e. to test whether ecstasy/MDMA use
was associated with diﬀerences in sleep-dependent memory
consolidation.
Multiple regressions were then performed to establish
associations between lifetime drug use and mean scores on
each of the memory tasks. Lifetime drug use variables and
their residuals were not normally distributed, so these regres-
sions were run with the non-parametric rank regression pro-
cedure on Minitab version 15. To avoid multicollinearity of
drug use variables, the control group participants were not
included in these lifetime drug use analyses. Lifetime usage of
ecstasy tablets and of MDMA (grams) were entered ﬁrst,
other drug usage and demographic and personality variables
were then entered stepwise with p> 0.05 set as the criterion
for removal of variables from the regression, until the most
predictive model was established in terms of the Jaecket–
Hettmansperger–McKean test statistic HM (Hollander and
Wolfe, 1999). Further analyses were also conducted with
NART IQ, gender, sleep length and personality variables
entered ﬁrst into the regression equations, with drug variables
entered second. Semi-partial correlations were also computed.
Results
Drug consumption, personality, sleep and mood
analyses
Table 1 shows the lifetime drug histories and current drug use,
including alcohol and tobacco, for the three groups. Drug
frequency and usual dose refer to the past year; there is
thus no cannabis frequency nor cannabis usual dose for the
non-drug control group. The control and two ecstasy/
MDMA groups did not diﬀer signiﬁcantly on alcohol fre-
quency or usual alcohol dose. Number of cigarettes consumed
per day was signiﬁcantly lower for controls than for recent
ecstasy/MDMA users (Mann-Whitney U¼ 38.00, z¼ 3.41,
p¼ 0.001) and abstinent ecstasy/MDMA users (Mann-
Whitney U¼ 22.00, z¼ 3.23, p¼ 0.001). The two ecstasy/
MDMA groups did not diﬀer signiﬁcantly on reported life-
time use of any of the drugs. The only signiﬁcant diﬀerence
between the two ecstasy/MDMA groups in current drug use
was in MDMA frequency, which was signiﬁcantly higher for
the recent ecstasy/MDMA group than for the abstinent group
(Mann-Whitney U¼ 88.50, z¼ 2.76, p¼ 0.005).
Table 2 shows the group mean scores on the personality,
sleep, and diary period mean mood and mood variability
measures. The groups were signiﬁcantly diﬀerent on time of
going to sleep at weekends and time of going to sleep on work
days. The recent ecstasy/MDMA group was signiﬁcantly
lower in Morningness than was the control group, but the
groups did not diﬀer on self-reported usual time of maximum
alertness, which for all groups was in the afternoon. None of
the variables that we speculated might be confounds in the
study (i.e. NART IQ; Conscientiousness; Locus of Control,
Morningness and mean sleep length prior to testing) were
signiﬁcantly related to both group membership and to task
performance (the only signiﬁcant relationship between any of
these variables and performance was between internal Locus
of Control and mean RBMT score: r¼ 0.27, p< 0.05).
Nevertheless, these ﬁve variables were introduced into the
recency of ecstasy/MDMA use regression analyses to assess
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Table 1. Lifetime and usual dose and frequency drug consumption for the control, recent ecstasy/MDMA and abstinent ecstasy/MDMA groups
Controls n¼ 24 Recent ecstasy/MDMA n¼ 25 Abstinent ecstasy/MDMA n¼ 17
Alcohol ever (n) 24 25 17
Alcohol this year (n) 24 25 17
Alcohol usual dose (units) 8.42 (5.24) 12.48 (11.17) 10.24 (5.61)
Alcohol frequency 138.71 (74.07) 183.04 (82.23) 208.47 (110.78)
Tobacco ever (n) 12 25 16
Tobacco this year (n) 11 24 15
Tobacco, cigarettes per day 2 (1.55) 9.79 (7.56)** 7.30 (4.90)**
Cannabis ever (n) 9 25 16
Cannabis lifetime consumption (joints) 3.6 (2.9) 3771.1 (8057.1) 2969.3 (4764.0)
Cannabis this year (n) 0 22 11
Cannabis usual dose (joints) 2.93 (2.65) 2.15 (1.29)
Cannabis frequency (per year) 155.77 (149.65) 79.36 (101.09)
Ecstasy ever (n) 0 25 17
Ecstasy lifetime consumption (tablets) 268.8 (274.9) 422.1 (511.6)
Ecstasy this year (n) 0 23 16
Ecstasy usual dose (tablets) 3.48 (2.29) 3.31 (1.29)
Ecstasy frequency 40.22 (36.27) 39.25 (29.22)
MDMA ever (n) 0 23 17
MDMA lifetime consumption (g) 43.5 (49.0) 48.9 (102.4)
MDMA this year (n) 0 23 17
MDMA usual dose (g) 0.68 (0.30) 0.66 (0.45)
MDMA frequency 57.09 (57.53)* 23.69 (26.51)*
Cocaine ever (n) 0 24 15
Cocaine lifetime consumption (g) 47.6 (68.7) 55.6 (63.3)
Cocaine this year (n) 0 24 14
Cocaine usual dose (g) 0.86 (0.40) 0.98 (0.82)
Cocaine frequency 31.42 (35.32) 40.79 (40.39)
Amphetamine ever (n) 0 14 12
Amphetamine lifetime consumption (g) 18.2 (19.3) 47.4 (101.8)
Amphetamine this year (n) 0 11 4
Amphetamine usual dose (g) 0.98 (0.57) 1.00 (0.71)
Amphetamine frequency 23.64 (32.59) 53.75 (58.04)
Ketamine ever (n) 0 23 11
Ketamine lifetime consumption (g) 25.9 (73.8) 70.0 (151.0)
Ketamine this year (n) 0 22 10
Ketamine usual dose (g) 0.70 (0.66) 0.86 (0.69)
Ketamine frequency 16.52 (17.92) 21.10 (19.87)
Mushrooms ever (n) 0 16 10
Mushrooms lifetime consumption (hits) 7.4 (6.4) 12.2 (7.0)
Mushrooms this year (n) 0 8 4
Mushrooms frequency 2.75 (2.12) 2.25 (1.89)
LSD ever (n) 0 10 7
LSD lifetime consumption (tabs) 7.2 (9.4) 20.1 (30.0)
LSD this year (n) 0 5 4
LSD usual dose (tabs) 1.40 (0.55) 1.75 (0.50)
LSD frequency 2.60 (1.34) 3.00 (2.00)
Heroin (non-IV) ever (n) 0 1 1
Heroin lifetime consumption (g) 2.0 0.1
Poppers ever (n) 0 19 12
Poppers lifetime consumption (hits) 90.8 (150.3) 140.5 (276.1)
Poppers this year (n) 0 13 7
Poppers usual dose (hits) 8.38 (8.53) 8.86 (8.09)
Poppers frequency 9.92 (11.52) 13.29 (14.36)
Notes:
Usual dose and frequency refer to drug consumption over the past year.
Means and SDs include only participants who report having taken the drug during the period specified (lifetime or past year).
*Ecstasy groups differ from each other at p¼ 0.005, Mann Whitney.
**Each ecstasy group differs from controls at p¼ 0.001, Mann Whitney.
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whether they are confounds. Gender was also entered into the
regression analyses, although there were no gender diﬀerences
on any personality, drug consumption, IQ, sleep or perfor-
mance (RBMT and FTT) variable.
There were no signiﬁcant diﬀerences between the groups
on alcohol consumption on the evening before each perfor-
mance testing session, on time since last use of caﬀeine prior
to the ﬁrst testing session, on time since last use of nicotine
prior to the ﬁrst testing session, nor on mean mood variables
(happy/sad and tense/relaxed) for the day of the ﬁrst testing
session (mood scores and time since last use of caﬀeine and
nicotine were not collected on the second testing day). There
was a signiﬁcant diﬀerence between the groups on sleepiness
at the start of the ﬁrst session (controls, mean¼ 2.21
(SD¼ 0.83); recent ecstasy/MDMA, mean¼ 3.00 (0.87);
abstinent ecstasy/MDMA, mean¼ 2.65 (1.32); ANOVA
F(2,63)¼ 3.92, p¼ 0.025), but not at the end of that session
nor at the start or end of the second session.
Memory performance analyses
The upper panel of Table 3 shows the means on the three
RBMT recall testing times for the control, recent ecstasy/
MDMA and abstinent ecstasy/MDMA groups. There was a
signiﬁcant eﬀect of test time (F(2,126)¼ 30.49, p< 0.001),
with signiﬁcant decreases in recall between the immediate
and 20min delayed testing sessions (Sidak pairwise compari-
son, p< 0.001) and between 20min delayed testing and 24 h
delayed testing (Sidak pairwise comparison, p< 0.05). There
was no interaction between group and change in recall across
test times (F(4,126)¼ 1.23). The three groups diﬀered signif-
icantly from each other (F(2,63)¼ 3.22, p< 0.05), with a post
hoc one-tailed Dunnett test for the main eﬀect showing that
recent ecstasy/MDMA users scored signiﬁcantly worse than
controls (p< 0.025). Over the three test times the recent
ecstasy/MDMA users recalled 76.1% of the level of control
group recall.
Non-parametric rank regressions were performed to inves-
tigate the association between memory and recency of
ecstasy/MDMA use. A continuous recency variable was com-
puted as the reciprocal of the number of days since last use of
ecstasy or MDMA. This varied from a maximum of 0.5
(reciprocal of 2 days) to 0 (meaning ecstasy or MDMA had
never been consumed). This recency variable was entered into
a regression as a predictor of the mean of the three RBMT
test time scores, and the mean of the two FTT speed scores.
For all the participants taken together, recency of ecstasy/
MDMA use predicted RBMT score with standardized
beta¼0.217, p¼ 0.01. When gender was entered into the
regression the standardized beta for the recency vari-
able¼0.220, p< 0.01; the standardized beta for gender
was not signiﬁcant. When the Morningness, diary mood, var-
iation in diary mood, NART IQ and pre-testing session sleep
length variables from Table 2, and pre-testing session alcohol
consumption and day of testing mood variables were entered
into the regression, the recency of taking ecstasy/MDMA
remained signiﬁcantly associated with mean RBMT score
with, in all cases, standardized beta being negative and of
greater magnitude than 0.20, and with p< 0.025. Negligible
decreases in the size of the beta for the regression of RMBT
Table 2. Means of IQ, personality, sleep and diary mood variables for the control, recent ecstasy/MDMA and abstinent ecstasy/MDMA groups
Controls n¼ 24 Recent ecstasy/MDMA n¼ 25 Abstinent ecstasy/MDMA n¼ 17
ANOVA
Mean SD Mean SD Mean SD F(2,63)
NART Full IQ 114.25 5.39 113.04a 4.60 117.24a 3.90 4.04*
Conscientiousness 39.83 2.97 39.44 4.41 40.88 3.92 0.74
Internal locus of control 34.38 5.75 30.68 3.79 31.74 8.04 2.56
Usual sleep quality 2.21 0.51 2.56 0.77 2.35 0.61 1.85
Time of going to sleep on work days 0 : 16 1 : 16 0 : 58 1 : 24 0 : 00 1 : 05 3.39*
Time of going to sleep on weekends1 1 : 32bc 1 : 23 3 : 23c 2 : 02 3 : 18b 1 : 28 8.76***
Time of waking on work days 8 : 42 1 : 17 9 : 22 1 : 36 8 : 51 1 : 14 1.52
Time of waking on weekends1 10 : 13 1 : 59 11 : 18 1 : 35 10 : 50 1 : 19 2.46
Morningness 31.46b 6.02 26.12b 5.40 27.47 6.03 5.49**
Time of maximum alertness 14 : 47 3 : 43 15 : 27 2 : 57 14 : 14 4 : 15 0.60
Mood across diary: happy/sad 36.59 9.49 35.37 15.38 39.33 10.06 0.54
Mood across diary: tense/relaxed 59.80 11.86 62.05 12.59 57.23 10.40 0.85
Variation in happy/sad across diary 17.38 5.99 17.33 7.91 17.31 7.10 0.00
Variation in tense/relaxed across diary 18.18 4.09 19.95 8.68 18.89 6.68 0.42
Sleep length on night before testing session 1 8 : 03 1 : 38 7 : 47 2 : 32 7 : 30 2 : 27 0.30
Sleep length on night before testing session 2 7 : 26 1 : 12 7 : 46 3 : 02 7 : 34 1 : 32 0.15
Note:
1Recent Ecstasy/MDMA n¼ 24, Abstinent Ecstasy/MDMA n¼ 16; ANOVA F has dfs (2,61).
*p< 0.05.
**p< 0.01.
***p< 0.001.
abetween groups comparison p< 0.025, Dunnett test.
bbetween groups p< 0.01, Dunnett test.
cbetween groups comparison p¼ 0.001, Dunnett test.
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score onto recency of ecstasy/MDMA consumption occurred
after entry of Locus of Control (beta for ecstasy/MDMA
recency¼0.17, p< 0.05), mean sleepiness (beta for
ecstasy/MDMA recency¼0.19, p¼ 0.025) and conscien-
tiousness (beta for ecstasy/MDMA recency¼0.20,
p< 0.025). In all cases where a potentially confounding vari-
able was entered into the regression equation, the beta for the
potential confounding variable was non-signiﬁcant with
p> 0.1. However, one confound did occur: when participants
who reported having taken illicit drugs in the period 48–24
hours prior to testing were excluded from the regression, the
standardized beta became negligible and non-signiﬁcant
(beta¼0.01). The drugs reported to have been consumed
in this period were cocaine, ketamine, amphetamine and can-
nabis. Those who had taken illicit drugs in this period were 16
of the recent ecstasy/MDMA users and two abstinent ecstasy/
MDMA users. The diﬀerence between the three groups on the
repeated measures ANOVA also became non-signiﬁcant
(F(2,45)¼ 0.20) when these individuals were excluded.
To examine further this confound of other drug use, the
lower panel of Table 3 reports the comparison of RBMT
scores for the controls and for the recent ecstasy/MDMA
users divided into those who did (n¼ 16) versus those who
did not (n¼ 9) consume illicit drugs in the period 48–24 hours
before testing. (As only two members of the abstinent ecstasy/
MDMA users group had taken other illicit drugs in this
48–24 h period, further sub-group analysis was not possible
for that group.) The controls and recent ecstasy/MDMA sub-
groups diﬀered on RMBT scores (F(2,46)¼ 3.95, p< 0.05),
with recent ecstasy/MDMA users who had taken other
drugs in the period 48–24 h before testing scoring signiﬁcantly
worse than controls (one-tailed Dennett test, p< 0.01), and
with recent ecstasy/MDMA users who had not taken other
drugs scoring worse than controls, but not signiﬁcantly so.
Importantly, comparisons on various drug use variables
between the recent ecstasy/MDMA users who used (n¼ 16)
or did not use (n¼ 9) illicit drugs 48–24 h prior to testing
(presented in Table 4) show that those who consumed these
other drugs reported signiﬁcantly less frequent use of ecstasy
tablets, but similar usual dose of ecstasy tablets to the
non-other drug use sub-group, and non-signiﬁcantly higher
frequency and usual dose of MDMA and cannabis, and
higher lifetime cannabis usage. All other lifetime and usual
drug use was very similar between the two sub-groups. Those
who took illicit drugs in the 48–24 h prior to testing reported
signiﬁcantly higher use of MDMA in the 2–3 days prior to
testing, but non-signiﬁcantly fewer ecstasy tablets (median
ecstasy tablets for those who took illicit drugs ¼ 0.25;
median ecstasy tablets for those who did not take illicit
drugs ¼ 2.0). There two sub-groups did not diﬀer signiﬁcantly
in usual or pre-performance testing nicotine or alcohol use, in
sleep length before either of the testing sessions, nor in sleep-
iness at the beginning or end of either testing session.
FTT speed on the ﬁrst three trials of the second session
(controls, mean¼ 20.04 (SD¼ 5.22); recent ecstasy/MDMA,
mean¼ 20.12 (5.32), abstinent ecstasy/MDMA¼ 21.35
(6.12)) was signiﬁcantly higher than on the last three trials
of the ﬁrst session (controls, mean¼ 17.68 (SD¼ 5.09); recent
ecstasy/MDMA, mean¼ 17.40 (5.86); abstinent ecstasy/
MDMA¼ 19.10 (5.65)), F(1,61)¼ 34.11, p< 0.001. This
increase did not interact with group (F(2,61)¼ 0.12). The
three groups did not diﬀer signiﬁcantly on FTT speed
(F(2, 61)¼ 0.44) and regression analysis showed that recency
of taking ecstasy/MDMA had a non-signiﬁcant standardized
beta (¼0.06) for predicting mean FTT speed score across
the six trials. There was a signiﬁcant decrease in errors
between the testing sessions (F(1,61)¼ 7.22, p< 0.01), which
did not interact with group (F(2,61)¼ 0.05), and the three
groups did not diﬀer on FTT errors (F(2,61)¼ 0.81).
Memory performance analyses across 24 h
for participants who had at least 7 h sleep
In order to address the hypothesized eﬀect of ecstasy/MDMA
on sleep-dependent memory consolidation for RBMT perfor-
mance, between-subjects repeated measures ANOVAs were
run with the score on the second (20min delayed memory)
and third (24 h delayed memory) tests as the repeated mea-
sure, for individuals who had obtained at least 7 h sleep on
Table 3. Scores on Rivermead Behavioral Memory Test for (upper panel) controls, recent ecstasy/MDMA and abstinent ecstasy/MDMA groups, and for
(lower panel) controls, recent ecstasy/MDMA users who reported no use of other illicit drugs 48–24 h before testing, and recent ecstasy/MDMA users
who reported other illicit drug use 48–24 h before testing
Immediate recall
20min
delayed recall
24 h
delayed recall
Main effect
planned comparisonan Mean SD Mean SD Mean SD
Controls 24 9.56* 3.73 8.60 3.47 8.19* 3.67
p< 0.025
Recent ecstasy/MDMA users 25 7.48* 2.78 6.66 3.05 5.90* 2.99
Abstinent ecstasy/MDMA users 17 8.91 2.72 8.03 2.67 8.09 2.37
Controls 24 9.56* 3.73 8.60* 3.47 8.19** 3.67
p< 0.01
Recent ecstasy/MDMA users with other illicit drug use 16 6.78* 2.37 5.91* 2.16 5.13** 2.19
Recent ecstasy/MDMA users without other illicit drug use 9 8.72 3.15 8.00 4.01 7.28 3.80
Notes:
All participants reported no drug use in the 24 h before testing.
aone-tailed Dunnett test.
*and *groups differ p< 0.025, one-tailed Dunnett test.
**and **groups differ p< 0.01, one-tailed Dunnett test.
]
]
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each of the nights before the two testing sessions. Participants
now included in the analysis are thus: controls, n¼ 11; recent
ecstasy/MDMA users, n¼ 13; and abstinent ecstasy/MDMA
users, n¼ 10. The means obtained are similar to those
presented in Table 3 and so are not presented here. There
was no interaction of test day with group (F(2,31)¼ 1.53),
and thus no eﬀect of ecstasy/MDMA on the memory consol-
idation function of sleep for the declarative task. These
three groups diﬀered signiﬁcantly on RBMT recall
(F(2,31)¼ 5.63, p< 0.01), with recent ecstasy/MDMA users
scoring signiﬁcantly worse than controls (one-tailed
Dunnett test, p< 0.005). As with the complete sample, this
signiﬁcant group diﬀerence disappeared if individuals who
reported having taken illicit drugs in the period 48–24 h
prior to testing were excluded (F(2,23)¼ 2.55).
The FTT ANOVAs were then re-run for individuals who
had obtained at least 7 h sleep on each of the nights before
testing. Participants now included in the analysis are thus:
controls, n¼ 11; recent ecstasy/MDMA, n¼ 12; abstinent
ecstasy/MDMA, n¼ 9; ns diﬀer from the RBMT analysis
because two participants were unable to learn the task. The
means obtained are similar to those presented for FTT above.
The interaction of test day with group remained non-signiﬁ-
cant for the FTT speed (F(2,29)¼ 0.09) and error analyses
(F(2,29)¼ 0.13). There was thus no eﬀect of ecstasy/MDMA
on the memory consolidation function of sleep for the proce-
dural memory task.
Associations of memory with lifetime
ecstasy/MDMA use
Non-parametric rank regressions were run to investigate the
prediction of the mean RBMT and mean FTT scores by
lifetime drug use. Lifetime usage was chosen as the long-
term measure of total drug use as it had correlations with
the two mean memory scores that, in general for the drugs
reported, exceeded other possible total drug use measures,
such as current frequency, current dose and the product of
frequency and dose. Table 5 shows the non-parametric mul-
tiple regression results for lifetime drug use predictors of
mean score on RBMT and FTT.
RBMT. Ecstasy lifetime usage and MDMA lifetime
usage were ﬁrst entered into the regression as predictors.
As the continuous variable recency of use of ecstasy/
MDMA and the dichotomous variable use of other ille-
gal drugs 48–24 h before testing had been found to be
related to RBMT score, these were also entered at this
time. Both MDMA lifetime usage and recency of use
of ecstasy/MDMA were found to have non-signiﬁcant
standardized betas and were hence removed from the regres-
sion: this resulted in Model 1. The next best predictor of
RBMT score, cocaine lifetime usage, was then entered,
which resulted in Model 2. Addition of any other life-
time drug usage or trait (e.g. personality, gender) or state
(e.g. pre-testing mood, sleep length, or alcohol consumption)
variable failed to add to the predictive value of the
model, and all these other variables also had non-signiﬁcant
standardized betas when entered into the regression.
RBMT score was thus predicted by lifetime ecstasy tab-
let usage, lifetime cocaine usage, and the consumption
of illicit drugs other than ecstasy/MDMA 48–24 h
before testing. Semi-partial correlations showed that the
variance in declarative memory was marginally more asso-
ciated with lifetime cocaine than lifetime ecstasy tablet
usage.
Table 4. Comparison of ecstasy, MDMA and cannabis consumption for recent ecstasy/MDMA users who took versus did not take illicit drugs1 48–24 h
prior to testing
Recent ecstasy/MDMA users
who did not take illicit drugs
48–24 h prior to testing (n¼ 9)
Recent ecstasy/MDMA users
who took illicit drugs1 48–24 h
prior to testing (n¼ 16) Comparison
between groups
(Mann-Whitney test)Mean SD Mean SD
Ecstasy lifetime usage (tablets) 252.78 155.76 277.75 328.27 n.s.
Ecstasy frequency (per year) 66.44 37.06 20.44 24.14 p< 0.001 U¼ 14.00 z¼ 3.38
Ecstasy usual dose (tablets) 2.94 2.70 3.34 2.29 n.s.
MDMA lifetime usage (g) 35.11 45.39 42.81 51.28 n.s.
MDMA frequency (per year) 43.33 39.04 57.69 66.05 n.s.
MDMA usual dose (g) 0.48 0.36 0.70 0.32 n.s.
Cannabis lifetime usage (joints) 1318 2799 4998 9583 n.s.
Cannabis frequency (per year) 63.00 71.41 178.75 166.61 n.s.
Cannabis usual dose (joints) 1.72 1.48 3.07 3.10 n.s.
Ecstasy tablets consumed 2–3 days prior to testing 2.94 2.96 2.84 6.28 n.s.
MDMA consumed 2–3 days prior to testing (g) 0.11 0.22 0.48 0.46 p< 0.05 U¼ 29.50 z¼ 2.50
Note:
1Drugs reported were: only amphetamine (n¼ 1), only ketamine (n¼ 1), only cocaine (n¼ 2), ketamine and cannabis (n¼ 1), cocaine and cannabis (n¼ 3) and only
cannabis (n¼ 8).
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FTT. Ecstasy lifetime usage and MDMA lifetime usage
were ﬁrst entered into the regression as predictors of
FTT mean speed. Recency of use of ecstasy/MDMA and
the dichotomous variable use of illicit drugs 48–24 h before
testing were not predictive of FTT speed and were not
entered into this regression. MDMA lifetime usage was
found to have a negligible and non-signiﬁcant beta
(beta¼0.01) and so was removed. Model 1 thus had
ecstasy lifetime usage as the signiﬁcant predictor of FTT.
The next largest predictor, cocaine lifetime usage, was then
added, but it did not improve the predictive value of the
model and the standardized beta for lifetime cocaine use
was non-signiﬁcant. Addition of any other lifetime drug
usage or trait or state variable failed to add to the predic-
tive value of the model, and all these variables had non-
signiﬁcant betas. FTT score was thus predicted only by
lifetime ecstasy tablet usage.
Negligible changes to these RBMT and FTT regression
results occurred when NART IQ, gender, sleep length and
personality variables were entered ﬁrst and held in the regres-
sion equations with drug variables entered second.
Discussion
Recent ecstasy/MDMA users showed a signiﬁcant deﬁcit in
declarative verbal memory, on the RBMT, compared with
non-drug controls. Recency of ecstasy/MDMA use, as a con-
tinuous variable that included recent, abstinent and non-
ecstasy/MDMA users, was also signiﬁcantly associated with
poorer declarative memory. This association remained signif-
icant when prior alcohol consumption, prior sleep length,
sleepiness during the task, NART estimated pre-morbid IQ,
gender and speciﬁc personality variables were controlled for.
The similarity between the groups in mood before the ﬁrst
testing session, and in mood and variation in mood across the
diary period, indicates that mood was not a confound for the
declarative memory performance results. The ecstasy/
MDMA-using participants were heavier smokers than the
Table 5. Regression results for predictors of mean scores on the Rivermead Behavioral Memory Test and the Finger Tapping Task for ecstasy/MDMA users
(n¼ 42)
Dependent variable, model,
and rejected predictors Significant predictors Ba SEa Betaa HMb pc
Semi-partial
correlation
RBMT
Enter: Ecstasy lifetime usage;
MDMA lifetime usage;
recency of taking ecstasy/MDMA;
use of illicit drugs 48–24 h
before testingd
Model 1
Ecstasy lifetime usage 0.0023 0.0012 .20 4.96 <0.05 0.33
Use of illicit drugs
48–24 h before testing
2.3252 0.8921 0.64 8.58 <0.005 0.43
Rejected (p> 0.05):
MDMA lifetime usage
Recency of taking ecstasy/MDMA
10.73 (df¼ 2) <0.005
Enter: Cocaine lifetime usage
Model 2
Ecstasy lifetime usage 0.0018 0.0010 0.15 4.23 <0.05 0.27
Use of illicit drugs
48–24 h before testing
2.5202 0.7509 0.69 11.37 <0.001 0.46
Cocaine lifetime usage 0.0154 0.0058 0.16 7.69 <0.01 0.35
19.25 (df¼ 3) <0.001
FTT speed
Enter: Ecstasy lifetime usage;
MDMA lifetime usagede
Model 1
Rejected (p> 0.05):
MDMA lifetime usage
Ecstasy lifetime usage 0.0052 0.0026 0.17 4.99 <0.05 .35
Notes:
RBMT Model 1, F(2,39)¼ 4.68; Model 2, F(3,38)¼ 6.18; FTT Model 1, F(1,40)¼ 4.55.
aNonparametric rank regression statistics, with rank regression standardized beta.
bJaecket–Hettmansperger–McKean nonparametric test statistic HM.
cHM statistic is converted to p by reference to Chi Square distribution (Hollander and Wolfe, 1999). HM has df¼ 1 unless otherwise stated.
dNART IQ, gender, sleep length, sleepiness, personality and consumption of alcohol, caffeine and nicotine were non-significant with p> 0.1 as predictors of RBMT score
and FTT speed.
eRecency of taking ecstasy/MDMA and use of illicit drugs 48–24 h before testing were both non-significant with p> 0.1 as predictors of FTT speed.
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controls, but given that participants were not required to
abstain from smoking, there should be minimal performance
eﬀects related to nicotine. Caﬀeine use prior to testing did not
diﬀer between groups, and so it was also unlikely to be a
confound.
In a more detailed analysis, it was found that this associ-
ation of recent ecstasy/MDMA use with poorer declarative
recall was only signiﬁcant for participants who also reported
having used other illicit drugs 48–24 h prior to testing.
Importantly, those individuals who used other illicit drugs
did not have a greater usual use of ecstasy or MDMA than
those who did not take other illicit drugs prior to testing.
However, there were a number of diﬀerences between those
participants who did and those who did not take other illicit
drugs during the 48–24 h pre-test period that may account for
the diﬀerences in RBMT score. Firstly, given that cannabis
was the most prevalent illicit drug used in this 48–24 h period,
it may be that the residual eﬀects of cannabis lasted until
testing. A second possibility follows from the ﬁnding that
the ecstasy/MDMA-using participants who used illicit drugs
in this period were heavier cannabis users. These participants
may thus have had greater substance dependence for canna-
bis, and this may have impacted on their performance as a
result of the required abstinence from all illicit drugs for 24 h
before testing (Solowij and Battisti, 2008). Thirdly, it is pos-
sible that there was an interaction between the recent ecstasy/
MDMA use and some or all of the other illicit drugs taken,
which resulted in greater performance deﬁcits. The latter pos-
sibility is consistent with investigators who have attributed
memory deﬁcits in ecstasy/MDMA users to the concurrent
recent use of cannabis and other drugs (Croft et al., 2001;
Gouzoulis-Mayfrank and Daumann, 2006; Lamers et al.,
2006). It is also consistent with Pirona and Morgan (2010),
who observed no sub-acute eﬀects of ecstasy/MDMA on
objective verbal recall performance, after controlling for
sleep deprivation and concurrent use of other substances.
However, ﬁnally, there was a signiﬁcantly higher recent use
of MDMA by those participants who took other illicit drugs
prior to testing, and this may have contributed to the declar-
ative memory deﬁcits.
The procedural memory performance of recent and absti-
nent ecstasy/MDMA users did not diﬀer from controls. This
is consonant with Zakzanis et al. (2007), who concluded that
ecstasy/MDMA does not cause motor skill deﬁcits. However,
the ﬁnding that the abstinent ecstasy/MDMA group did not
show declarative memory deﬁcits does appear to contradict
Zakzanis et al. (2007) and many other reports (e.g. Reneman
et al., 2001; Reneman et al., 2006; Thomasius et al., 2005).
The latter ﬁndings, though, have not been completely consis-
tent: for example, Reneman et al. (2001) reported that
ecstasy/MDMA users recalled signiﬁcantly fewer words
than controls on delayed, but not immediate recall, and
Thomasius et al. (2005) reported that only former ecstasy/
MDMA users, and not current users, had signiﬁcantly
poorer verbal recall. Furthermore, although Reneman et al.
(2006) reported that heavy current and also heavy former
ecstasy/MDMA users performed signiﬁcantly worse on
memory tasks than controls, there was no evidence of
memory deﬁcits in moderate ecstasy/MDMA users. There
are, however, numerous studies that have shown signiﬁcant
declarative memory deﬁcits associated with chronic ecstasy/
MDMA use (see review by Parrott, 2006; Indlekofer et al.,
2009; Rendell et al., 2007).
Nevertheless, the present study did provide some evidence
that ecstasy/MDMA consumption is implicated in chronic
declarative and procedural memory deﬁcits. Multiple regres-
sion indicated that lifetime usage of ecstasy tablets and of
cocaine were predictors of deﬁcits in declarative memory.
The association of declarative memory deﬁcits with lifetime
ecstasy use is consistent with Thomasius et al. (2005), Schilt
et al. (2008) and de Sola Llopis et al. (2008), and with the view
that MDMA induces neurotoxicity (e.g. Gouzoulis-Mayfrank
et al., 2003). Montgomery et al. (2007) had similarly found
that lifetime ecstasy and cocaine use were associated with
deﬁcits in paired-associate learning, even after sleepiness
was controlled for. The association with lifetime cocaine use
may be consistent with evidence that cocaine disrupts the
hypothalamic-pituitary-adrenal axis as a result of its action
on 5-HT1A autoreceptors, such as the ﬁnding of down-
regulation of 5-HT1A receptors in rat hypothalamus and den-
tate gyrus after ‘binge’-pattern cocaine administration
(Perrett et al., 1998). It has also been suggested that since
psychostimulants are neurotoxic upon both serotonergic
and dopaminergic neurons they may act synergistically with
MDMA and enhance its long-term adverse eﬀects
(Gouzoulis-Mayfrank and Daumann, 2006). Multiple regres-
sion analysis also indicated that only lifetime usage of ecstasy
tablets was a signiﬁcant predictor of deﬁcits in FTT proce-
dural memory. This novel ﬁnding is consistent with pre-
clinical evidence that 5-HT might modulate this type of
learning at the level of the basal ganglia (e.g. Perez-Garcia
and Meneses, 2008), and thus may be susceptible to MDMA-
induced neurotoxicity. However, it is unclear why the
reported lifetime consumption of ecstasy tablets was associ-
ated with declarative and procedural memory deﬁcits,
whereas lifetime consumption of grams of MDMA powder
was not. This may indicate that estimations of powder
MDMA use are less accurate than estimations of number of
tablets consumed, either because powder mass may be diﬃ-
cult to assess, or because powders have more instances where
they can be subject to adulteration than do tablets.
There was no support for the second and third hypotheses,
of ecstasy/MDMA causing a deﬁcit in sleep-dependent
memory consolidation for the declarative and procedural
tasks used here. Whether this holds for sleep-dependent
memory consolidation of other declarative or procedural
tasks remains to be determined. However, Tucker and
Fishbein (2009) have recently demonstrated that post-sleep
performance gains on a declarative paired associates task
and on the procedural FTT are very similar regardless of
whether subjects obtain a half night or a full night of sleep.
It may thus be that the mild eﬀects of ecstasy/MDMA on
sleep length and quality are not suﬃcient to disrupt sleep-
dependent memory consolidation for the tasks used in their
and our studies.
Recent and abstinent ecstasy/MDMA users had lower
Morningness than controls. Future research should assess
whether this is a result of extreme evening preference types
choosing to take ecstasy/MDMA, or whether this increased
eveningness is a result of ecstasy/MDMA use. The latter is a
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possibility as circadian rhythms are aﬀected by MDMA in
hamsters (Colbron et al., 2002) and rats (Balogh et al.,
2004). However, it should be noted that Morningness scales
in general, including the one used here, do confound individ-
ual diﬀerences in alertness across the day with habitual bed
and wake times. Future work should thus address whether,
relative to habitual wake up time, ecstasy/MDMA users and
non-users diﬀer in their pattern of alertness across the day.
From the results here, all groups had their maximum alertness
approximately 5.5–6 h after waking: frequent ecstasy/MDMA
use does not therefore seem to be altering the pattern of alert-
ness across the day.
The present study suﬀered from a number of methodolog-
ical limitations. One was that we decided not to undertake
assays to conﬁrm substance use. Our rationale for this was
that we considered it an unnecessary burden on participants,
since recent studies involving serum checks have conﬁrmed
the accuracy of self-reported ecstasy/MDMA usage and absti-
nence (Parrott et al., 2008; Pirona and Morgan, 2010).
Furthermore, Thomasius et al. (2003) reported very high con-
cordance between self-reported ecstasy/MDMA use and the
results of hair analyses. Also, Parrott (2004) noted the high
purity of ecstasy tablets, so that taking ‘ecstasy’ tablets typi-
cally results in MDMA ingestion. There were other method-
ological limitations that are generic to naturalistic studies of
ecstasy/MDMA users, including diﬃculties recruiting poly-
drug users who had never consumed ecstasy/MDMA and,
as a consequence, diﬃculties statistically controlling for the
possible inﬂuence of other illicit drugs. There was also the
fundamental limitation inherent to all cross-sectional studies
of being unable to infer causality.
One of the implications of the present ﬁndings is that
ecstasy-induced neurotoxicity may result in procedural as
well as declarative memory deﬁcits, and therefore that
limbic 5-HT/dopamine interactions may play a more prom-
inent role in procedural memory than hitherto recognized.
Ecstasy-induced neurotoxicity may also impact upon 5-HT
and dopamine interactions in parallel, functionally segre-
gated, cortico-striatal circuits thought to modulate aspects
of impulsive responding (Fineberg et al., 2010; Morgan,
1998). Alternatively, since striatal dopamine transmission
is implicated in both procedural learning (Willuhn and
Steiner, 2009) and impulsivity (Fineberg et al., 2010), it is
possible that the association between the extent of ecstasy
use and procedural memory is due to pre-existing diﬀerences
in impulsivity. The clinical implications of our observed
association between deﬁcits in procedural learning and the
extent of lifetime ecstasy consumption might include an
increased risk that regular ecstasy users will exhibit deteri-
oration in the improvement of new simple motor skills.
More generally, memory deﬁcits will adversely aﬀect numer-
ous aspects of everyday functioning. For example, Reay
et al. (2006) found that drug-free ecstasy/MDMA users
had signiﬁcantly poorer social intelligence, which was
related to the MDMA-associated deﬁcits in memory updat-
ing. Furthermore, Topp et al. (1999) noted many further
deﬁcits in ecstasy/MDMA users, including occupational
stress and interpersonal diﬃculties, and these could also
be related to or exacerbated by the additional stress of def-
icits in memory and cognition.
In summary, recent ecstasy/MDMA use was associated
with signiﬁcant declarative memory deﬁcits, but only when
there was also use of other illicit drugs, in particular cannabis,
48–24 h prior to testing. Caution is therefore required in inter-
preting earlier studies where recent use of other drugs has not
been assessed or controlled. Recent ecstasy/MDMA use was
not associated with procedural memory deﬁcits. Higher levels
of lifetime ecstasy tablet usage were signiﬁcantly associated
with declarative and procedural memory deﬁcits. Finally, the
recreational use of ecstasy/MDMA did not aﬀect the memory
consolidation function of sleep for the declarative and proce-
dural tasks used in this study.
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